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Objectives We sought to determine whether the blood pressure (BP) levels at which cardiovascular (CV) protection is
achieved differ between diabetic and nondiabetic patients from the ONTARGET (ONgoing Telmisartan Alone and
in combination with Ramipril Global
Endpoint Trial).
Background Greater absolute benefits of BP reductions have been claimed for diabetic as compared with nondiabetic patients.
Methods A total of 25,584 patients (9,603 diabetic), older than 55 years, at high CV risk were randomized to ramipril,
telmisartan, or both and observed for 4.6 years. We pooled the treatment arms to examine the relationships
between BP and the primary composite outcome (CV death, nonfatal myocardial infarction or stroke, or hospital-
ized heart failure) and its components.
Results The primary outcome occurred in 1,938 (20.2%) diabetic patients and in 2,276 (14.2%) nondiabetic patients.
Compared with nondiabetic patients, diabetic patients had a significantly higher risk for the primary endpoint
(hazard ratio [HR]: 1.48; 95% confidence interval [CI]: 1.38 to 1.57) and CV death (HR: 1.56; 95% CI: 1.42 to
1.71); myocardial infarction (HR: 1.30 (95% CI: 1.17 to 1.46); stroke (HR: 1.39; 95% CI: 1.23 to 1.56); and con-
gestive heart failure hospitalization (HR: 2.06; 95% CI: 1.82 to 2.32). The CV risk was significantly higher in dia-
betic than in nondiabetic patients regardless of the systolic BP changes during treatment. In both diabetic and
nondiabetic patients, progressively greater systolic BP reductions were accompanied by reduced risk for the pri-
mary outcome only if baseline systolic BP levels ranged from 143 to 155 mm Hg; except for stroke, there was
no benefit in fatal or nonfatal CV outcomes by reducing systolic BP below 130 mm Hg.
Conclusions The relationship between BP and overall CV risk had a similar pattern in diabetic and nondiabetic patients
over a wide range of baseline and in-treatment BP values although, for the same systolic BP, a higher risk
is observed in diabetic patients. (Ongoing Telmisartan Alone and in Combination With Ramipril Global
Endpoint Trial [ONTARGET]; NCT00153101) (J Am Coll Cardiol 2012;59:74–83) © 2012 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.09.040Observational studies have shown that the cardiovascular
(CV) sequelae of diabetes increase progressively with in-
creased blood pressure (BP) across a large range of BP
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documented that in diabetes, BP reductions by drug treat-
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December 27, 2011/January 3, 2012:74–83 Blood Pressure in High-Risk Diabetesmacrovascular and microvascular complications (5–8). Fi-
nally, greater absolute benefits of BP reductions have been
claimed for diabetic as compared with nondiabetic patients,
although a meta-analysis concluded that there was limited
vidence that lower BP goals produced larger reductions in
otal major CV events in individuals with diabetes compared
ith those without (9).
Guidelines have recommended more aggressive antihyper-
tensive treatment in diabetes, aiming at values 130 mm Hg
systolic and 80 mm Hg diastolic. However, the additional
beneficial effects of such lower BP targets remain unproven
(8–12). The recent results of the ACCORD (Action to
Control Cardiovascular Risk in Diabetes) (13), showed that in
patients with type 2 diabetes, targeting systolic BP to 120
mm Hg did not reduce the rate of CV events, compared with
subjects in whom the systolic BP target was 140 mm Hg,
xcept for stroke. Likewise, a post hoc analysis of the INVEST
International Verapamil SR-Trandolapril Study) concluded
hat reducing systolic BP to 130 mm Hg in patients with
iabetes and coronary artery disease was not associated with
mproved CV outcomes compared with usual BP control (14).
The recently published ONTARGET (ONgoing
elmisartan Alone and in combination with Ramipril
lobal Endpoint Trial) (15) provides an opportunity to
etermine in a large number of patients whether the BP
t which CV protection is achieved differs between
iabetic and nondiabetic patients during treatments
ased on blockade of the renin-angiotensin system. We
ave analyzed the data to examine this question. In
ddition, we have explored whether BP reduction in
igh-risk diabetic patients impacts outcomes differently
han in nondiabetic patients.
ethods
etween January 2002 and June 2003, 25,584 patients
lder than 55 years, of whom 9,603 had diabetes, were
andomized to ramipril, telmisartan, or both in a multi-
enter double-blind trial performed in 40 countries. The
ligibility criteria and details of the protocol have been
eported previously (16,17). Briefly, patients had to have
or more previous CV events or diabetes with end-organ
amage. After written informed consent, patients entered
single-blind run-in period in which they received
amipril and telmisartan in progressive doses for 3 to 4
on the Speaker’s Bureau for Boehringer-Ingelheim, Daiichi Sankyo, Forest Pharmaceu-
ticals, and Novartis; and serves as a consultant for Boehringer-Ingelheim, Bristol-Myers
Squibb, Daiichi Sankyo, Forest Pharmaceuticals, Novartis, and Takeda Pharmaceuticals.
Dr. Bohm has received study and speaker fees from Boehringer-Ingelheim. Dr. Williams
has received a research grant from Boehringer-Ingelheim as an investigator in the
ONTARGET study. Dr. Yusuf has received research grants and honoraria for speaking
and consulting from Sanofi, Boehringer-Ingelheim, Bristol-Myers Squibb, Novartis, and
Servier. All other authors have reported that they have no relationships relevant to the
contents of this paper to disclose. Part of these data were presented at the Milan meeting
of the European Society of Hypertension, Milan, Italy, June 2008.H
Manuscript received February 23, 2011; revised manuscript received September 15,
2011, accepted September 19, 2011.eeks. Patients who tolerated
he run-in period were then
andomized to receive 80 mg of
elmisartan once daily, 5 mg of
amipril once daily, or their
ombination for 2 weeks. The
ose of ramipril was increased
o 10 mg in the 2 relevant arms.
Except for angiotensin-converting enzyme inhibitors
r angiotensin receptor blockers, the addition of other
ntihypertensive drugs was allowed to achieve the target
P values recommended by guidelines in high-risk pa-
ients. Follow-up visits occurred at 6 weeks, 6 months,
nd then every 6 months until the last scheduled visit. At
ach visit, BP was measured in duplicate after a 3-min
est with the patient in the sitting position using a
emiautomatic validated (18) device (Model HEM-757,
MRON Healthcare, Vernon Hills, Illinois). BP values
rom baseline to the time of the event or to the final
rotocol visit were used for the analysis.
The primary outcome of the study was a composite of CV
eath, myocardial infarction, stroke, or hospitalization for
ongestive heart failure as adjudicated by a central commit-
ee. Secondary outcomes were the primary outcome com-
onents. Since in the Cox regression model the relation
etween outcome and treatment allocation showed no
ignificant differences, and treatment uniformly consisted of
rugs blocking the renin-angiotensin system, data for the 3
reatment groups were pooled to allow the analysis to be
ade on a large number of patients.
tatistical analysis. Analyses were conducted with SAS
.2 release (SAS Institute, Cary, North Carolina) using
he Cox regression model. Since the trial included pa-
ients above 55 years of age, data analysis was focused on
ystolic BP, which in the elderly is more predictive than
iastolic BP (19).
The relation between baseline systolic BP, divided into
uartiles (first: 95 to 130 mm Hg, second: 131 to 142 mm Hg,
hird: 143 to 154 mm Hg, and fourth: 155 to 200 mm Hg),
nd risk of the primary and other outcomes was explored using
ox regression, as well as the relation between outcome and
he magnitude of systolic BP changes during follow-up, di-
ided into tertiles, for each systolic BP entry quartile. We
ested for a quadratic relationship of outcome with in-
reatment systolic BP, because the relationship was nonlinear.
he nadir was derived from the resulting quadratic function,
nd confidence intervals (CIs) were calculated using the delta
ethod (20). The risk of primary as well as of other outcomes
n patients with or without diabetes at baseline was calculated
efore and after adjustment for age, gender, and the following
aseline covariates: current smoking, ethnicity, body mass
ndex, serum creatinine, history of CV disease, and use of
spirin, statins, diuretics, or beta-blockers. We did not adjust
he association of systolic BP and outcomes for pulse pressure
ecause of the strong colinearity between the 2 measures.
Abbreviations
and Acronyms
BP  blood pressure
CI  confidence interval
CV  cardiovascular
HR  hazard ratioazard ratios (HRs) and 95% CIs were calculated in estimat-
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Blood Pressure in High-Risk Diabetes December 27, 2011/January 3, 2012:74–83ing the levels of risk. Finally, characteristics of patients who
suffered from a myocardial infarction or died because of CV
disease were compared with those who did not experience an
event by using analysis of variance. In these 2-tailed tests, p
values 0.05 were considered significant. No corrections were
ade for multiple testing.
esults
aseline characteristics of the study population and
escription of outcomes. The general characteristics of the
tudy population, including treatments other than the trial
edication, are shown in Table 1, separately for diabetic
nd nondiabetic patients. During the 4.5 years of follow-up
median: 4.6 years), the primary outcome occurred in 1,938
20.2%) diabetic patients and in 2,276 (14.2%) nondiabetic
atients. There was also a relatively large number of cause-
pecific CV events that were more common in diabetic than
n nondiabetic patients. The respective figures were 506
5.3%) and 622 (3.9%) for strokes, 544 (5.7%) and 710
4.4%) for nonfatal myocardial infarctions, 868 (9.0%) and
48 (5.9%) for CV deaths, and 587 (6.1%) and 492 (3.1%)
ospital admissions for heart failure. Compared with non-
iabetic patients, diabetic patients had a significantly higher
isk for the main outcome (HR: 1.48, 95% CI: 1.38 to 1.57)
nd cause-specific events: CV death (HR: 1.56; 95% CI:
.42 to 1.71); myocardial infarction (HR: 1.30; 95% CI:
.17 to 1.46); stroke (HR: 1.39; 95% CI: 1.23 to 1.56);
ongestive heart failure hospitalization (HR: 2.06; 95% CI:
.82 to 2.32).
aseline systolic BP and outcomes. Figure 1 shows the
nadjusted Kaplan-Meier plots for outcomes in relation to
uartiles of systolic BP value. For the same baseline systolic
P, diabetic patients consistently had a higher risk of the
rimary outcome and of all its components than nondiabetic
atients. There was a statistically significant association
etween baseline systolic BP and the incidence of stroke in
oth diabetic and nondiabetic patients (p  0.01, compar-
ng stroke incidence in the first with the third or fourth
uartiles). Stroke was primarily responsible for the progres-
ively higher incidence of the primary outcome with higher
aseline systolic BP because there was no relationship
etween baseline systolic BP and the incidence of other
vents, that is, CV death, myocardial infarction, or hospi-
alized heart failure.
Table 2 shows the HRs for the primary outcome and
ts components in relation to baseline systolic BP, taking
he lowest systolic BP quartile of nondiabetic patients as
he reference. Diabetic subjects had higher risk than
ondiabetic patients whichever systolic BP quartile was
onsidered. In both diabetic patients and nondiabetic
atients, there were significant differences between the
rst and the third and fourth quartiles for stroke. In
ontrast, no between-quartile differences were seen for
he primary outcome, CV mortality, myocardial infarc-
ion, and hospitalized heart failure. Compared with the rrst quartile, the second quartile showed a lower risk of
yocardial infarction and heart failure, but this disap-
eared with data adjustment.
ystolic BP changes during treatment and outcomes. In-
reatment BP values were the mean of all the values before
he event or until the final visit, excluding baseline values.
s shown in Figure 2, treatment reduced systolic BP in each
aseline systolic BP quartile, the average in-treatment quar-
ile values being 125.8 12.0 mm Hg, 132.4 11.2 mm Hg,
37.7  11.5 mm Hg, and 144.3  12.6 mm Hg. The CV
General Characteristics of the Study PopulationTable 1 General Characteristics of the Study Population
Nondiabetic
Patients
(n  15,981)
Diabetic
Patients
(n  9,603)
Demographics
Female 3,663 (22.9) 3,154 (32.8)
Age, yrs 66.6 7.4 66.1 6.7
Ethnicity
European/Caucasian 12,376 (77.1) 6,432 (67.0)
Asians 2,001 (12.5) 1,519 (15.8)
Black African 268 (1.7) 301 (3.1)
Other 1,334 (5.3) 1,351 (14.1)
Medical history
Hypertension 9,991 (62.5) 7,601 (79.2)
Current smoking 2,149 (13.4) 1,075 (11.2)
CAD 13,144 (82.3) 5,929 (61.7)
MI 8,886 (55.6) 3,644 (38.0)
Angina 7,819 (48.9) 3,668 (38.2)
PAD 2,040 (12.8) 1,424 (14.8)
Stroke/TIA 3,360 (21.0) 1,566 (16.4)
Medication
Beta-blockers 9,743 (60.9) 4,831 (50.3)
Calcium channel blockers 4,911 (30.7) 3,554 (37.0)
Diuretics 3,686 (23.0) 3,472 (36.2)
Statins 10,519 (65.7) 5,253 (54.7)
ASA 12,799 (80.0) 6,590 (68.6)
ACE inhibitors 8,468 (52.9) 6,272 (65.3)
ARB 1,154 (7.2) 1,054 (11.0)
Insulin 0 (0) 2,653 (27.6)
Oral glucose-lowering agents 0 (0) 6,425 (66.9)
Physical, mean
SBP, mm Hg 140.7 17.6 143.7 16.91
DBP, mm Hg 82.2 10.5 81.8 10.28
Pulse pressure, mm Hg 81.8 11.0 61.9 13.84
Body mass index 27.5 29.3 29.2 4.91
Laboratory, mean
Serum creatinine, mmol/l 96.8 26,4 95.0 27.6
Glucose, mmol/l 5.5 1.0 8.6 3.2
Cholesterol, mmol/l 4.9 1.1 5.0 1.2
HDL, mg/dl 1.3 0.4 1.2 0.4
LDL, mg/dl 2.9 1.0 2.9 1.0
Triglycerides mmol/l 1.7 1.0 1.9 1.3
Values are n (%) or mean  SD.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; ASA  aspirin;
CAD  coronary artery disease; DBP  diastolic blood pressure; HDL  high-density lipoprotein;
LDL low-density lipoprotein; MImyocardial infarction; PAD peripheral artery disease; SBP
systolic blood pressure; TIA  transitory ischemic attack.isk was significantly higher in diabetic patients than in
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December 27, 2011/January 3, 2012:74–83 Blood Pressure in High-Risk Diabetesnondiabetic patients regardless of the systolic BP change
during treatment. In both diabetic patients and nondiabetic
patients, the progressively greater systolic BP reduction
from the first to the third tertile was accompanied by a
reduction in the risk for the primary outcome only if
baseline systolic BP ranged from 143 to 155 mm Hg. With
1 exception, this was the case also for stroke, the progres-
sively greater systolic BP reduction from the first to the
third tertile was usually associated with no reduction in
either CV mortality or myocardial infarction. In any case, no
significant interaction was observed for BP and diabetes in
the outcomes risk. The results were similar when data were
adjusted for covariates (data not shown). In the adjusted
data, there was no evidence of any adverse effect of low
Figure 1 Kaplan-Meier Curves Relating Baseline SBP
Systolic blood pressure (SBP) measurements were divided into quartiles (first: 95
200 mm Hg), to the cumulative hazard of the primary outcome (A), stroke (B), my
nondiabetic patients.systolic BP on any CV outcome, except for CV mortality,which in patients with a baseline systolic BP 130 mm Hg
showed a significant increase in the tertile with the greatest
systolic BP reduction. In this low baseline systolic BP
quartile, the risk of CV mortality increased progressively
from the tertile with a small systolic BP increase to that with
a larger systolic BP reduction (p  0.01 for trend). Conse-
quently, the beneficial impact of BP reduction was similar in
both groups of subjects although the risk reduction was
greater in diabetic patients as compared with nondiabetic
patients as a result of the highest baseline risk.
The incidence of CV events for deciles of in-treatment
systolic BP is shown in Figure 3. There was a progressive
reduction in the incidence of stroke down to 115 mm Hg
systolic BP. In contrast, a “J-curve” relationship was ob-
mm Hg, second: 131 to 142 mm Hg, third: 143 to 154 mm Hg, fourth: 155 to
al infarction (C), and cardiovascular mortality (D), in both diabetic patients andto 130
ocardiserved for the other outcomes. For the primary outcome, the
u78 Redon et al. JACC Vol. 59, No. 1, 2012
Blood Pressure in High-Risk Diabetes December 27, 2011/January 3, 2012:74–83nadir of the J-curve lay at about 129.6 mm Hg (122.1 to
137.0 mm Hg) systolic BP for diabetic patients and 129.0
mm Hg (123.9 to 134.1 mm Hg) for nondiabetic patients.
For CV death, it lies at 135.6 mm Hg (130.6 to 140.5 mm Hg)
and 133.1 mm Hg (128.8 to 137.4 mm Hg), respectively, in
diabetic patients and nondiabetic patients. No nadir was
observed for myocardial infarction or stroke. Achieving
systolic BP of 130 mm Hg instead of 140 mm Hg reduced
the risk for the primary outcome by 3.4% in diabetic
Risk of Primary Study Outcome and Other Outcome Events AccordTable 2 Risk of Primary Study Outcome and Other Outcome Ev
Model
H
Primary Composite
Outcome
Cardiovascular
Death
Unadjusted
Quartile 1
No DM 1.00 1.00
DM 1.46 (1.37–1.55) 1.55 (1.41–1.70
Quartile 2
No DM 0.93 (0.85–1.02) 0.97 (0.85–1.11
DM 1.36 (1.22–1.51) 1.51 (1.29–1.76
Quartile 3
No DM 1.03 (0.94–1.12) 0.97 (0.85–1.11
DM 1.50 (1.35–1.66) 1.50 (1.29–1.76
Quartile 4
NO DM 1.18 (1.09–1.28)* 1.11 (0.98–1.26
DM 1.72 (1.56–1.90)† 1.71 (1.47–1.99
Adjusted by age and sex
Quartile 1
No DM 1.00 1.00
DM 1.54 (1.45–1.64) 1.65 (1.50–1.81
Quartile 2
No DM 0.91 (0.83–0.99)† 0.94 (0.82–1.07
DM 1.39 (1.25–1.55) 1.55 (1.32–1.81
Quartile 3
No DM 0.97 (0.89–1.06) 0.90 (0.79–1.02
DM 1.49 (1.35–1.66) 1.48 (1.26–1.73
Quartile 4
No DM 1.07 (0.98–1.16) 0.96 (0.84–1.09
DM 1.64 (1.49–1.81) 1.58 (1.36–1.84
Full adjustment‡
Quartile 1
No DM 1.00 1.00
DM 1.35 (1.25–1.46) 1.38 (1.22–1.55
Quartile 2
No DM 0.92 (0.84–1.01) 0.97 (0.85–1.11
DM 1.25 (1.11–1.41) 1.34 (1.12–1.60
Quartile 3
No DM 0.97 (0.89–1.06) 0.89 (0.78–1.03
DM 1.31 (1.17–1.47) 1.23 (1.03–1.47
Quartile 4
No DM 1.05 (0.96–1.15) 0.96 (0.84–1.10
DM 1.42 (1.27–1.60) 1.32 (1.11–1.57
Quartiles of baseline systolic blood pressure (in mm Hg):130,130 to142,142 to154,
diabetic patient group; ‡adjusted by the following covariates (all included in the model): age (years
(kg/m2), serum creatinine (mg/l), plasma glucose (mg/dl), low-density lipoprotein cholesterol (mg/
se of aspirin, statins, diuretics, or -blockers (yes or no).
CHF  congestive heart failure; DM  diabetes mellitus; SBP  systolic blood pressure.patients and 4% in nondiabetic patients; for CV death, 0%and 1.9%; for myocardial infarction 3.7% and 0.1%; and
for stroke 31.4% and 21.7%, respectively.
Influence of in-trial diastolic BP. The association be-
tween in-trial diastolic BP and outcomes at any level of
achieved systolic BP is shown in Figure 4. For the primary
outcome, both diabetic and nondiabetic patients showed
that the highest risk occurred in subjects with the lowest or
highest in-trial diastolic BP (67.2 and 86.7 mm Hg,
respectively), whatever the systolic BP values. The increase
SBP at Entry (First Visit)According to SBP at Entry (First Visit)
Ratio (95% Confidence Interval)
Myocardial
Infarction
Hospitalization
Due to CHF Stroke
1.00 1.00 1.00
1.30 (1.16–1.45) 2.06 (1.83–2.32) 1.33 (1.18–1.50)
0.82 (0.70–0.96)* 0.83 (0.70–0.98)* 1.17 (0.97–1.40)
1.07 (0.88–1.30) 1.71 (1.39–2.10) 1.55 (1.25–1.93)
0.87 (0.74–1.02) 0.89 (0.75–1.05) 1.47 (1.23–1.75)*
1.13 (0.94–1.36) 1.84 (1.51–2.24) 1.95 (1.59–2.40)†
1.07 (0.92–1.24) 0.94 (0.80–1.10) 1.83 (1.54–2.16)*
1.39 (1.16–1.66) 1.93 (1.59–2.35) 2.43 (2.00–2.96)†
1.00 1.00 1.00
1.37 (1.22–1.53) 2.16 (1.92–2.44) 1.38 (1.23–1.56)
0.81 (0.69–0.95)* 0.80 (0.67–0.95)* 1.14 (0.95–1.36)
1.11 (0.92–1.34) 1.73 (1.40–2.12)† 1.57 (1.27–1.95)
0.85 (0.72–0.99)* 0.82 (0.69–0.97)* 1.39 (1.17–1.66)*
1.16 (0.96–1.39) 1.77 (1.45–2.16)† 1.92 (1.57–2.36)†
1.02 (0.87–1.18) 0.81 (0.68–0.95)* 1.66 (1.40–1.96)*
1.39 (1.16–1.66) 1.74 (1.43–2.12)† 2.30 (1.88–2.80)†
1.00 1.00 1.00
1.39 (1.20–1.60) 1.64 (1.41–1.91) 1.33 (1.14–1.54)
0.86 (0.73–1.01) 0.88 (0.74–1.04) 1.10 (0.91–1.33)
1.19 (0.96–1.48) 1.44 (1.15–1.81) 1.46 (1.15–1.85)
0.88 (0.75–1.04) 0.89 (0.75–1.06) 1.29 (1.08–1.55)*
1.23 (0.99–1.52) 1.46 (1.17–1.83) 1.72 (1.36–2.16)†
1.06 (0.91–1.24) 0.86 (0.73–1.02) 1.47 (1.24–1.75)*
1.47 (1.19–1.81) 1.42 (1.13–1.77) 1.95 (1.56–2.44)†
 0.05 referred to quartile 1 within nondiabetic patient group; †p 0.05 referred to quartile 1 within
er, smoking (current, formerly, never), ethnicity (Caucasian, Asian, Black, other), body mass index
ory of cardiovascular diseases (previous myocardial infarction, previous stroke, angina [yes or no]),ing toents
azard
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
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trend was observed for CV mortality, whereas myocardial
infarction showed no distinct pattern. Compared with the
remaining 3 quartiles, the risk for stroke was maximal in the
quartile with the highest diastolic BP value.
Characteristics of the group with a low systolic BP at
baseline. In patients with a systolic BP 130 mm Hg at
aseline, the characteristics of patients who suffered from a
yocardial infarction or died for CV disease were compared
ith those who did not experience an event (Table 3). In
oth the diabetic and nondiabetic groups, patients who
uffered an event had an older age, a previous history of
oronary or peripheral artery disease, a lower ankle–arm BP
atio, a higher heart rate, a higher serum creatinine value,
nd a greater use of diuretics. Diabetic patients who suffered
rom an event also had more insulin treatment and more
requent smoking. In contrast, no differences in baseline and
ean BP changes during treatment were observed. In a Cox
azard risk analysis of the subjects with initial systolic BP
130 mm Hg, after adjusting for the baseline variables, the
isk to have events was increased in diabetes (HR: 1.29, 95%
Figure 2 Tertile Changes in SBP Induced by Treatment
and Cardiovascular Outcomes
Changes within each quartile of baseline systolic blood pressure (SBP) in
diabetic patients and nondiabetic patients are shown. CV  cardiovascular.I: 1.05 to 1.58), older age (HR: 1.04, 95% CI: 1.03 to1.05), current smokers (HR: 1.52, 95%CI: 1.19 to 1.95),
high creatinine levels (HR: 2.23, 95% CI: 1.72 to 2.90),
previous myocardial infarction (HR 1.72, 95% CI: 1.43 to
2.07), previous angina (HR: 1.48, 95% CI: 1.25 to 1.75),
and use of diuretics (HR: 1.56, 95% CI: 1.31 to 1.86). In
contrast, treatment with statins (HR: 0.76, 95% CI: 0.63 to
0.91) was associated with lower risk. Concerning BP values,
increment in systolic BP was associated with lower risk
(HR: 0.98, 95% CI: 0.97 to 0.99), whereas increment in
diastolic BP was associated with higher risk (HR: 1.02, 95%
CI: 1.00 to 1.03). An increment in systolic BP of 10 mm Hg
was associated with risk reduction by 13% and an increment
in DBP with increment of risk by 18%.
Discussion
Our post-hoc analysis of the large ONTARGET database
shows that in patients with a history of CV disease or
diabetes with end-organ damage, the incidence of CV
morbidity and fatal events was markedly higher (adjusted
risk about 50%, 30%, and 40% for CV mortality,
myocardial infarction, and stroke, respectively) in the pres-
ence of diabetes at each level of baseline or achieved BP.
This confirms the results of previous studies (21,22) that
diabetes sharply increases CV risk and that this occurs
regardless of the BP level. It also shows that diabetes
continues to magnify CV risk, even in patients at high CV
risk for other reasons.
The principal finding of the present study is that the
relationship between BP and overall CV risk had a similar
pattern in diabetic and nondiabetic patients over a wide range
of baseline and in-treatment BP values. The role of diabetes
was to shift the relationship of events with BP upward
compared with that in the nondiabetic group. So, we can
suggest that as far as the relationship with BP is concerned
there may be no reason to consider diabetics separately from
other high-risk patients. This applies also to the effect of
BP-lowering treatment. In this respect, our findings do not
support the claim that the relationship between BP reductions
and CV risk reduction is steeper in diabetes (9), and it is
agreement with a recent published study (23).
In the diabetic patients, the risk of stroke showed a
clear-cut relationship with systolic BP throughout a wide
range of initial and in-treatment values. The adjusted risk of
stroke continued to decrease down to achieved systolic BP
values of 115 mm Hg, with no evidence of an upward
J-curve inflection. This is consistent with the conclusions
drawn from retrospective analyses of trials on patients with
a history of stroke (24) or coronary heart disease (25,26),
which indicate that as far as protection against stroke is
concerned, the lower the achieved BP, the better.
The relationship of initial or in-treatment systolic BP
with myocardial infarction or CV mortality was different
from that for stroke because the risk of either event was not
significantly related to the baseline systolic BP value and was
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155 and 115 mm Hg. It should be emphasized that the
differing relationship of systolic BP to stroke and to cardiac
Figure 3 Proportion of Outcome Events by Achieved SBP, Divid
The quadratic relationship between in-treatment systolic blood pressure (SBP) and
CV  cardiovascular.
Figure 4 Primary Outcome in Relation to Achieved DBP
Results are divided into quartiles and are for any level of achieved systolic blood p
DBP  diastolic blood pressure.events was the reason for the limited relationship of baseline
and in-treatment systolic BP with the primary composite
outcome, which included both types of events.
to Deciles
s is shown separately for diabetic patients and nondiabetic patients.
re (SBP) in both diabetic patients and nondiabetic patients.ed In
eventressu
 perc
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events appear to be parallel to those for diastolic BP. That
is, regardless of the in-treatment systolic BP, low achieved
Characteristics of the Patients Who Had MI or CV Death ComparedT ose That Did No Have Events in the Baseline Low BP Gr u (SBTable 3 Charact ristics of the Patient Who Had MI or CV D aThose That Did Not Have Events in the Baseline Low B
Nondiabetic Patients
No Events Events
n 3,722 (90.1) 410 (9.9)
Demographics
Female 777 (20.9) 65 (15.9)
Age 65.0 7.0 67.2 7.9
Age 65 yrs 1,781 47.9 239 58.3
Ethnicity
European/Caucasian 2,868 (77.1) 316 (77.1)
Asians 482 (13.0) 42 (10.2)
Black African 48 (1.3) 8 (2.0)
Other 324 (8.7) 43 (10.5)
Medical history
Hypertension 1,721 (46.2) 202 (49.3)
Current smoking 540 (14.5) 83 (20.3)
Angina 1,892 (50.8) 227 (55.4)
CAD 3,272 (87.9) 375 (91.5)
MI 2,375 (63.8) 301 (73.4)
PAD 354 (9.5) 63 (15.4)
Stroke/TIA 622 (16.7) 78 (19.0)
CABG or PTCA 2047 (55.0) 208 (50.7)
Medication
Beta-blockers 2,468 (66.3) 263 (64.1)
Calcium channel blockers 958 (25.7) 103 (25.1)
Diuretics 746 (20.0) 122 (29.8)
Statins 2,692 (72.3) 268 (65.4)
ASA 3,076 (82.6) 325 (79.3)
ACE inhibitors 2,013 (54.1) 254 (62.0)
ARB 236 (6.3) 22 (5.4)
Insulin — —
Oral glucose-lowering agents — —
Physical, mean
Heart rate, beats/min 65.4 12.0 68.3 12.4
SBP, mm Hg 118.7 8.1 118.1 8.7
DBP, mm Hg 73.8 8.4 72.4 9.1
Pulse pressure, mm Hg 44.9 8.5 45.7 9.4
SBP change,* mm Hg 5.1 12.3 4.4 14.4
DBP change,* mm Hg 0.3 8.7 0.2 10.2
Arm/leg BP ratio, right 0.92 0.28 0.96 0.18
Arm/leg BP ratio, left 0.92 0.33 0.95 0.20
Body mass index, kg/m2 27.2 4.2 27.1 4.5
Waist circumference, cm 94.2 12.7 94.7 12.8
Waist/hip ratio 0.94 0.08 0.95 0.08
Laboratory, mean
Serum creatinine, mg/dl 92.4 21.1 98.6 26.4
Glucose, mg/dl 5.4 0.9 5.5 1.1
Cholesterol, mg/dl 4.7 1.0 4.8 1.0
HDL, mg/dl 1.2 0.4 1.2 0.4
LDL, mg/dl 2.8 0.9 2.9 0.9
Triglycerides, mg/dl 1.6 1.0 1.6 0.9
Values are n (%) or mean  SD.
BP  blood pressure; CABG  coronary artery bypass graft surgery; CV  cardiovascular; PTCAdiastolic BP levels were associated with higher risks of theprimary outcome and myocardial infarction, whereas the
risk of stroke was greatest in the diabetic subjects in whom
the in-treatment diastolic BP was relatively high and least in
h30 mm Hg)mpared With
oup (SBP <130 mm Hg)
Diabetic Patients
p Value No Events Events p Value
1,597 (86.3) 253 (13.7)
0.0166 438 (27.4) 68 (26.9) 0.8556
0.0001 64.7 6.8 67.4 7.4 0.0001
0.0001 771 48.3 158 62.5 0.0001
0.1990 0.1049
1034 (64.7) 182 (71.9)
316 (19.8) 35 (13.8)
55 (3.4) 9 (3.6)
192 (12.0) 27 (10.7)
0.2431 1,058 (66.2) 170 (67.2) 0.7676
0.0019 236 (14.8) 33 (13.0) 0.4627
0.0814 646 (40.5) 137 (54.2) 0.0001
0.0339 1,083 (67.8) 211 (83.4) 0.0001
0.0001 722 (45.2) 148 (58.5) 0.0001
0.0002 175 (11.0) 51 (20.2) 0.0001
0.2360 256 (16.0) 49 (19.4) 0.1838
0.0997 683 (42.8) 117 (46.3) 0.2996
0.3801 875 (54.8) 151 (59.7) 0.1456
0.7861 478 (29.9) 76 (30.0) 0.9721
0.0001 547 (34.3) 139 (54.9) 0.0001
0.0030 966 (60.5) 147 (58.1) 0.4714
0.0891 1,168 (73.1) 198 (78.3) 0.0849
0.0025 1,007 (63.1) 193 (76.3) 0.0001
0.4433 157 (9.8) 18 (7.1) 0.1755
— 410 (25.7) 89 (35.2) 0.0016
— 1,069 (66.9) 157 (62.1) 0.1270
0.0001 70.7 12.1 73.0 14.8 0.0211
0.1708 119.6 7.9 118.7 8.6 0.1524
0.0021 72.9 8.6 71.9 9.3 0.0892
0.0856 46.6 8.9 46.9 9.5 0.7054
0.3552 8.7 12.7 9.1 15.2 0.6964
0.3359 1.2 8.8 2.1 10.4 0.2369
0.0003 0.93 0.18 0.98 0.20 0.0004
0.0019 0.93 0.18 0.99 0.30 0.0025
0.4788 29.1 5.4 29.4 6.1 0.4363
0.4666 97.9 14.1 100.0 15.3 0.0367
0.0104 0.95 0.08 0.96 0.08 0.0521
0.0001 93.3 25.5 110.0 35.2 0.0001
0.1333 8.2 3.1 8.7 3.3 0.0435
0.3348 4.8 1.1 4.8 1.3 0.4346
0.0520 1.2 0.4 1.1 0.4 0.0133
0.1546 2.7 0.9 2.8 1.0 0.7345
0.7485 1.9 1.4 2.2 1.6 0.0400
utaneous transluminal coronary angioplasty; other abbreviations as in Table 1.WitP <1th Co
P Grthose in whom the in-treatment diastolic BP was low. This
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the ONTARGET trial, in particular that about three-
quarters of the patients had a history of coronary disease,
with possibly a greater need for myocardial blood flow
preservation (27–29).
Other characteristics of the patients with a baseline
systolic BP 130 mm Hg who had an event (myocardial
infarction or CV death) were significantly different from
those who did not. Patients having an event had a greater
probability of pre-study vascular disease (coronary or pe-
ripheral artery disease) as well as being older, being more
likely to be on antidiabetic or antihypertensive treatment,
and having more evidence for renal dysfunction. In contrast,
there were only minimal differences between the 2 groups in
either initial or achieved BP levels. Although other expla-
nations are possible, this points to high baseline risk of the
patients being a key determinant of the J-curve phenome-
non, rather than a causal relationship with excessive BP
reduction.
Study limitations. First, retrospective analysis of nonran-
domized data might have allowed factors other than BP to
influence the results. Second, the ONTARGET population
was somewhat different from that usually seen in conven-
tional hypertension trials, particularly because of their high
rate of prior events. So, caution must be exercised in
extrapolating these results to younger diabetic patients at
lower cardiovascular risk, in whom “the lower the BP the
better” rule might still apply. Third, a large proportion of
patients were treated with antiplatelet therapy, -blockers,
nd statins, all of which reduce CV risk. This might have
inimized the potential benefit of BP-lowering strategies,
articularly at the lower BP entry values. Fourth, patients
ategorized into groups by BP showed marked differences in
ther risk factors, and despite extensive adjustments for
nown factors, these adjustments might have been inade-
uate or failed to include other unknown factors. Fifth, the
nalysis focuses on the average of in-treatment levels of BP
rior to a clinical event. It is subject to a greater degree of
nterpretation bias since we cannot eliminate the possibility
hat the BP effect on events was, in part, related to better BP
ontrol during the follow-up. Finally, the trial treatment
as based on blockers of the renin-angiotensin system. It
annot be determined whether the same relationship be-
ween baseline BP, BP reductions, and changes in CV risk
ould hold for treatment based on other drugs.
Our data have implications for the antihypertensive
reatment of diabetic patients, at least when this condition
nvolves patients with additional high CV risks. Antihyper-
ensive treatment should be expected to exert a clear-cut
rotective effect against macrovascular complications when
nitial systolic BP values are high. At lower initial systolic
P levels, in the 130 to 142 mm Hg range, the benefit of BP
eduction mainly originates from protection against stroke.
inally, around or below an initial systolic BP of 130 mm
g, antihypertensive treatment should be implemented
ith caution because of the possibility of untoward cardiacffects that could counterbalance the beneficial conse-
uences of aggressive BP reduction for stroke. This might
lso apply to diastolic BP values of 67 mm Hg or less.
learly, more evidence from prospective trials is necessary to
earn whether high-risk diabetic patients with BP levels
etween 130 and 140 mm Hg should be treated to lower BP
evels. As well, a prospective assessment of clinical markers
dentifying vulnerable patients in whom aggressive BP
eduction could be deleterious would be of value.
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